US 6,399,061 B1 · Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma

Abstract

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies. Preferred anti-CD20 antibodies are the monoclonal anti-body secreted by ATCC Deposit No. HB11388 and the chimeric anti-CD20 antibody secreted by transfectoma TCAE8 accorded ATCC Deposit No. 69119.

Claims7

Dependent claims

A method for depleting peripheral B cells in a host in need of such treatment comprising administering an amount of the anti-CD20 antibody produced by ATCC deposit number 69119 sufficient to induce B cell depletion.

Dependencies are inferred from the claim text.

Facts

Application

08/475,815Filed 7 Jun 1995 · division

Priority

13 Nov 1992

Granted

4 Jun 2002

Term ends

Not estimatedThe source records don’t support an estimate.

Classification22 codes

C07K 16/2887
Against receptors, cell surface antigens or cell surface determinants: against CD20
A61K 47/6849
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting a receptor, a cell…
A61K 51/1027
Antibodies or immunoglobulins; Fragments thereof , the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised…
A61K 51/1093
Antibodies or immunoglobulins; Fragments thereof , the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised…

Family

Application07/978,891Parent of this continuation-in-part · filed 13 Nov 1992

Application08/149,099Parent of this division · filed 3 Nov 1993

US 5,736,137 AParent of this division

Application08/149,099Parent of this continuation-in-part

US 6,399,061 B1This patent

From the US filing history. Foreign family members aren’t listed.

Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma

Life of this patent

Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma

Life of this patent

Abstract

Claims7